ITM and Alpha-9 Oncology Announce Global Supply Agreement to Support Alpha-9’s Clinical Radiopharmaceutical Development Program
January 30, 2024 07:00 ET
|
ITM Isotope Technologies Munich SE
GARCHING / MUNICH, Germany and VANCOUVER, British Columbia, January 30, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9),...
ITM Appoints Dr. Mark Harfensteller as Member of its Executive Board
January 16, 2024 05:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany, January 16, 2024 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Dr. Mark Harfensteller to its...
ITM Announces Operational Readiness for NOVA Facility, the World’s Largest Lutetium-177 Production Site
January 04, 2024 07:54 ET
|
ITM Isotope Technologies Munich SE
Receipt of Radioactive Material Handling License (RAM License) for production of n.c.a. Lutetium-177Progress demonstrates company’s ability to rapidly increase GMP manufacturing capabilities to...
ITM to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023 08:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany, December 21, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO, Steffen Schuster and CFO, Dr. Klaus...
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
December 14, 2023 09:28 ET
|
ITM Isotope Technologies Munich SE
ITM secures first-in-class folate precursors for radiolabeling to advance clinical and commercial development of its folate-based pipeline candidatesLicensing agreement broadens indication areas to...
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development and Commercialization of Folate-Based Radiotheranostics
December 14, 2023 09:26 ET
|
ITM Isotope Technologies Munich SE
ITM secures first-in-class folate precursors for radiolabeling to advance clinical and commercial development of its folate-based pipeline candidatesLicensing agreement broadens...
ITM Reports on Participation at 3rd ICPO Forum for Theranostics in Precision Oncology and Announces Support for ICPO Academy for Theranostics
October 24, 2023 08:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany, October 24, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today reported on its participation at the 3rd International...
ITM and CNL Announce the Launch of Actineer, a New Joint Venture in the Global Production of Actinium-225
October 18, 2023 08:00 ET
|
ITM Isotope Technologies Munich SE
New company will advance Actinium-225 technologies, quickly secure supply, and construct a new production facility in Canada to produce industrial-scale quantities of rare medical isotope ...
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
July 31, 2023 09:00 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, Germany and Indianapolis, IN, USA, July 31, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc. (NASDAQ:...
ITM to Host Theranostics Symposium on Clinical Need and Supply at SNMMI Annual Meeting on Sunday, June 25, 2023
June 15, 2023 04:23 ET
|
ITM Isotope Technologies Munich SE
Garching / Munich, June 15, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will host a multidisciplinary symposium titled,...